Literature DB >> 17292820

A radical role for p38 MAPK in tumor initiation.

Norman J Kennedy1, Cristina Cellurale, Roger J Davis.   

Abstract

It is established that p38 MAPK can negatively regulate tumorigenesis, but the mechanism is incompletely understood. A new study in this issue of Cancer Cell shows that p38 MAP kinase plays a selective role in tumor initiation mediated by oxidative stress.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17292820     DOI： 10.1016/j.ccr.2007.01.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  25 in total

1.  The roles of stress-activated Sty1 and Gcn2 kinases and of the protooncoprotein homologue Int6/eIF3e in responses to endogenous oxidative stress during histidine starvation.

Authors:  Naoki Nemoto; Tsuyoshi Udagawa; Takahiro Ohira; Li Jiang; Kouji Hirota; Caroline R M Wilkinson; Jürg Bähler; Nic Jones; Kunihiro Ohta; Ronald C Wek; Katsura Asano
Journal:  J Mol Biol       Date:  2010-09-25       Impact factor: 5.469

2.  Retinol induces morphological alterations and proliferative focus formation through free radical-mediated activation of multiple signaling pathways.

Authors:  Daniel Pens Gelain; Matheus Augusto de Bittencourt Pasquali; Fernanda Freitas Caregnato; Mauro Antonio Alves Castro; José Claudio Fonseca Moreira
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

3.  Anticancer effect of Tamarix gallica extracts on human colon cancer cells involves Erk1/2 and p38 action on G2/M cell cycle arrest.

Authors:  Mondher Boulaaba; Soninkhishig Tsolmon; Riadh Ksouri; Junkyu Han; Kiyokazu Kawada; Abderrazak Smaoui; Chedly Abdelly; Hiroko Isoda
Journal:  Cytotechnology       Date:  2013-06-26       Impact factor: 2.058

4.  Ultraviolet irradiation can induce evasion of colon cancer cells from stimulation of epidermal growth factor.

Authors:  Seiji Adachi; Ichiro Yasuda; Masanori Nakashima; Takahiro Yamauchi; Junji Kawaguchi; Masahito Shimizu; Masahiko Itani; Momoko Nakamura; Yumi Nishii; Takashi Yoshioka; Yoshinobu Hirose; Yukio Okano; Hisataka Moriwaki; Osamu Kozawa
Journal:  J Biol Chem       Date:  2011-06-06       Impact factor: 5.157

5.  miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response.

Authors:  Bogdan Mateescu; Luciana Batista; Melissa Cardon; Tina Gruosso; Yvan de Feraudy; Odette Mariani; André Nicolas; Jean-Philippe Meyniel; Paul Cottu; Xavier Sastre-Garau; Fatima Mechta-Grigoriou
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

6.  A monoclonal antibody (Mc178-Ab) targeted to the ecto-ATP synthase β-subunit-induced cell apoptosis via a mechanism involving the MAPKase and Akt pathways.

Authors:  Wen-Juan Wang; Zhan Ma; Yi-Wen Liu; Yi-Qing He; Ying-Zhi Wang; Cui-Xia Yang; Yan Du; Mu-Qing Zhou; Feng Gao
Journal:  Clin Exp Med       Date:  2011-04-20       Impact factor: 3.984

7.  OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway.

Authors:  Li-Yuan Bai; Yihui Ma; Samuel K Kulp; Shu-Huei Wang; Chang-Fang Chiu; Frank Frissora; Rajeswaran Mani; Xiaokui Mo; David Jarjoura; John C Byrd; Ching-Shih Chen; Natarajan Muthusamy
Journal:  Br J Haematol       Date:  2011-04-07       Impact factor: 6.998

Review 8.  The p38 MAPK stress pathway as a tumor suppressor or more?

Authors:  Mathew Loesch; Guan Chen
Journal:  Front Biosci       Date:  2008-05-01

9.  Attenuation of p38 MAPK activity upon contact inhibition in fibroblasts.

Authors:  Michael Slisz; Emily Rothenberger; Dorothy Hutter
Journal:  Mol Cell Biochem       Date:  2007-09-29       Impact factor: 3.396

10.  Down-regulation of miR-125a-5p is associated with salivary adenoid cystic carcinoma progression via targeting p38/JNK/ERK signal pathway.

Authors:  Yancan Liang; Jiantao Ye; Jiuyang Jiao; Jin Zhang; Yingjuan Lu; Li Zhang; Di Wan; Liming Duan; You Wu; Bin Zhang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.